Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy

被引：0
作者：
Marcellin, P
Lau, G
Piratvisuth, T
Luo, KX
Bonino, F
Thongasawat, S
Cooksley, G
Hadziyannis, S
Chutaputti, A
Lu, ZM
Fried, M
Chow, WC
Yurdaydin, C
Berg, T
Pluck, N
机构：
[1] Hop Beaujon, Clichy, France
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Songklanakarin Hosp, Songkhla, Thailand
[4] Nangfang Hosp, Guangzhou, Peoples R China
[5] IRCCS Osped Maggiore, Sci Direct, Milan, Italy
[6] Chiang Mai Univ, Chiang Mai 50000, Thailand
[7] Univ Queensland, Royal Brisbane Hosp, Herston, Qld, Australia
[8] H Dynant Hosp, Athens, Greece
[9] Pramongkutklao Hosp, Bangkok, Thailand
[10] Ruijin Hosp, Shanghai, Peoples R China
[11] Univ N Carolina, Chapel Hill, NC USA
[12] Singapore Gen Hosp, Singapore 0316, Singapore
[13] Ankara Univ, TR-06100 Ankara, Turkey
[14] Charite Humboldt Univ Berlin, Berlin, Germany
[15] Roche, Welwyn Garden City, England
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：668A / 668A
页数：1
相关论文
共 50 条
[31]   ALT flares in patients with HBeAg-positive chronic hepatitis B and treated with either conventional interferon alfa-2a or peginterferon alfa-2a (40KD) (PEGASYS®) are not necessary for a significant response to therapy. [J].
Cooksley, WGE ;
Lai, MY ;
Piratvisuth, T ;
Wang, YJ ;
Mahachai, V ;
Chao, YC ;
Tanwandee, T ;
Chutaputti, A ;
Chang, WY ;
Zahm, FE ;
Pluck, N .
HEPATOLOGY, 2003, 38 (04) :724A-724A
[32]   Asian patients with HBeAg-negative chronic hepatitis B respond well to peginterferon alfa-2a (40 KD) (PEGASYS®) treatment [J].
Jia, Ji-Dong ;
Piratvisuth, Teerha ;
Lau, George K. K. ;
Luo, Kang-Xian ;
Jin, Rui ;
Lu, Zhi-Meng ;
Marcellin, Patrick ;
Popescu, Matei ;
Button, Peter .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 :A88-A88
[33]   Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy [J].
Sherman, M. ;
Yoshida, E. M. ;
Deschenes, M. ;
Krajden, M. ;
Bain, V. G. ;
Peltekian, K. ;
Anderson, F. ;
Kaita, K. ;
Simonyi, S. ;
Balshaw, R. ;
Lee, S. S. .
GUT, 2006, 55 (11) :1631-1638
[34]   Efficacy of peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C in Germany -: A contribution to health care research [J].
Zehnter, E ;
Mauss, S ;
John, C ;
Heyne, R ;
Möller, B ;
Bokemeyer, B ;
Moog, G ;
Alshuth, U ;
Hüppe, D .
HEPATOLOGY, 2005, 42 (04) :683A-683A
[35]   Treatment of patients with chronic hepatitis C and normal alanine aminotransferase levels with peginterferon alfa-2a (40 KD) (Pegasys®) and ribavirin. [J].
Zeuzem, S ;
Diago-Madrid, M ;
Shiffman, ML ;
Reindollar, RW ;
Pockros, PJ ;
Gane, E ;
Tran, A ;
Farci, P ;
Lamour, F .
HEPATOLOGY, 2002, 36 (04) :583A-583A
[36]   Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin [J].
Ferenci, P ;
Fried, MW ;
Shiffman, ML ;
Smith, CI ;
Marinos, G ;
Gonçales, FL ;
Häussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxì, A ;
Chaneac, M ;
Reddy, KR .
JOURNAL OF HEPATOLOGY, 2005, 43 (03) :425-433
[37]   Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C. [J].
Jensen, CDM ;
Bernstein, DE ;
Hassanein, TI ;
Foster, GR ;
Lee, SS ;
Cheinquer, H ;
Craxi, A ;
Cooksley, WGE ;
Klaskala, W ;
Green, J .
HEPATOLOGY, 2002, 36 (04) :603A-603A
[38]   Efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS®) in patients with chronic hepatitis B who had received prior treatment with nucleos(t)ide analogues -: the PEGaLAM cohort [J].
Piratvisuth, Teerha ;
Boyer, Nathalie ;
Tanwandee, Tawesak ;
Huat, Robert Pooi ;
Gadano, Adrian ;
Mercado, Randy .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 :A32-A32
[39]   A dynamic model to predict sustained virological response to combination peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) therapy in patients with chronic hepatitis C. [J].
Ferenci, P ;
Fried, MW ;
Chaneac, M .
HEPATOLOGY, 2003, 38 (04) :635A-635A
[40]   Peginterferon alfa-2a (40kd) (Pegasys®) plus ribavirin in chronic hepatitis C:: Retreatment of patients who relapsed virologically after 24 weeks of therapy. [J].
Goncales, F ;
Bernstein, DE ;
Berg, C ;
Sette, H ;
Rasenack, J ;
Diago, M ;
Jensen, DM ;
Cooksley, WGE ;
Roberts, P ;
Ackrill, AM .
HEPATOLOGY, 2002, 36 (04) :361A-361A
12345